title: Magnesium sulfate for neuroprotection: what do we do now?
authors.forename: James R
authors.initials: JR
authors.lastname: Scott
mesh_terms: D002547:Cerebral Palsy / Q000517:prevention & control*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D008278:Magnesium Sulfate / Q000627:therapeutic use*; D011247:Pregnancy; D047928:Premature Birth / Q000517:prevention & control*; D015149:Tocolytic Agents / Q000627:therapeutic use*
chemical_list: D015149:Tocolytic Agents; D008278:Magnesium Sulfate
references.citation: Nelson KB, Grether JK. Causes of cerebral palsy. Curr Opin Pediatr 1999;11:487–91.
references.citation: Conde-Aguledo A, Romero R. Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeks' gestation: a systematic review and metaanalysis. Am J Obstet Gynecol 2009;200:595–609.
references.citation: Mercer BM, Merlino AA. Magnesium sulfate for preterm labor and preterm birth. Obstet Gynecol 2009;114:650–68.
references.citation: Pryde PG, Mittendorf R. Contemporary usage of obstetric magnesium sulfate: Indication, contraindication, and relevance of dose. Obstet Gynecol 2009;114:669–73.
references.citation: Rouse DJ. Magnesium sulfate for the prevention of cerebral palsy. Am J Obstet Gynecol 2009;200:610–2.